Oligonucleotide-based proteolysis targeting chimera
Compounds and pharmaceutical compositions useful to treat cancer (e.g., lymphoma), neurodegenerative diseases, and autoimmune disorders include (1) a first nucleic acid sequence capable of binding to a transcription factor, for example, a signal transducer and activator of transcription (STAT) factor, such as STAT3, (2) a second nucleic acid sequence capable of binding a Toll-like receptor protein, for example, a CpG oligodeoxynucleotide, and (3) a ubiquitin ligase binding compound capable of binding a ubiquitin ligase protein, for example, a compound that is capable of binding a cereblon protein, such as lenalidomide, pomalidomide, or thalidomide.
1. A compound comprising:
(i) a nucleic acid having at least 90% sequence identity to a nucleic acid selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO:8; and
(ii) one or more ubiquitin ligase binding compounds selected from the group consisting of:
wherein the nucleic acid is covalently bonded to the one or more ubiquitin ligase binding compounds.
2. The compound of claim 1 , wherein the one or more ubiquitin ligase binding compounds are selected from the group consisting of:
3. The compound of claim 1 , wherein the nucleic acid is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO: 8.
4. The compound of claim 1 , wherein the compound comprises from 1 to 5 ubiquitin ligase binding compounds.
5. The compound of claim 1 , wherein the nucleic acid has at least 95% sequence identity to the nucleic acid of SEQ ID NO:2 and the ubiquitin ligase binding compound is
6. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of claim 1 .
7. A method of treating lymphoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the compound of claim 1 .
8. A compound comprising:
(i) a signal transducer and activator of transcription 3 (STAT3) binding nucleic acid sequence,
(ii) a second nucleic acid sequence selected from the group consisting of a Class A CpG oligodeoxynucleotide, a Class B CpG oligodeoxynucleotide, or a Class C CpG oligodeoxynucleotide, and
(iii) a ubiquitin ligase binding compound capable of binding a cereblon protein;
wherein the ubiquitin ligase binding compound is covalently bound to (i) or (ii) through a linker having the formula:
wherein:
MC is the ubiquitin ligase binding compound,
L 1 is:
(a) —(PO 3 OH—(CH 2 ) pm ) pn —PO 3 OH—, wherein pm is an integer from 1 to 8; and pn is an integer from 1 to 10;
(b) —(CH 2 ) pc —(PO 3 OH—(CH 2 ) pm ) pn —PO 3 OH—; wherein pc is an integer from 0 to 6;
pm is an integer from 1 to 8; and pn is an integer from 1 to 10:
(c) —(CH 2 ) pc —(PO 3 OH—(CH 2 ) pm ) pn —; wherein pc is an integer from 0 to 6; pm is an integer from 1 to 8; and pn is an integer from 1 to 10;
(d) —(PO 3 OH—(CH 2 ) pm ) pn —PO 3 OH—(CH 2 ) po —NH—; wherein pm is an integer from 1 to 8; pn is an integer from 1 to 10; and po is an integer from 1 to 12;
(e) —(PO 3 OH—(CH 2 ) pm ) pn —PO 3 OH—[(CH 2 ) pa —O] pb —(CH 2 ) po —NH—; wherein pm is an integer from 1 to 8; pn is an integer from 1 to 10; po is an integer from 1 to 12; pa is an integer from 1 to 4; and pb is 0, 1, or 2; or
(f)
L 2 , L 3 , and L 4 are each independently substituted or unsubstituted polyglycol, substituted or unsubstituted C 1 -C 16 alkylene, substituted or unsubstituted 2 to 16 membered heteroalkylene, substituted or unsubstituted C 3 -C 20 cycloalkylene, substituted or unsubstituted 3 to 20 membered heterocycloalkylene, substituted or unsubstituted C 6 -C 20 arylene, or substituted or unsubstituted 6 to 20 membered heteroarylene.
9. The compound of claim 8 , wherein:
(i) the STAT3 binding nucleic acid sequence is SEQ ID NO:25 or SEQ ID NO:26;
(ii) the second nucleic acid sequence is SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24; and
(iii) the ubiquitin ligase binding compound is selected from the group consisting of:
10. The compound of claim 9 , wherein the ubiquitin ligase binding compound is selected from the group consisting of:
11. The compound of claim 8 , wherein the STAT3 binding nucleic acid sequence and the second nucleic acid sequence comprise a nucleic acid selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:7, and SEQ ID NO:8.
12. The compound of claim 8 , wherein the compound comprises from 1 to 5 ubiquitin ligase binding compounds.
13. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of claim.
14. A method of treating lymphoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the compound of claim 8 .
15. A compound comprising:
(i) a signal transducer and activator of transcription 3 (STAT3) binding nucleic acid sequence comprising a first STAT3 binding nucleic acid sequence and a second STAT3 binding nucleic acid sequence connected through a spacer, wherein the spacer is substituted or unsubstituted polyglycol, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
(ii) a second nucleic acid sequence selected from the group consisting of a Class A CpG oligodeoxynucleotide, a Class B CpG oligodeoxynucleotide, or a Class C CpG oligodeoxynucleotide, and
(iii) a ubiquitin ligase binding compound capable of binding a cereblon protein; wherein the ubiquitin ligase binding compound is covalently bound to (i) or (ii) through a linker.
16. The compound of claim 15 , wherein:
(i) the first STAT3 binding nucleic acid sequence is SEQ ID NO:25 and the second STAT3 binding nucleic acid sequence is SEQ ID NO:26;
(ii) the second nucleic acid sequence is SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, or SEQ ID NO:24; and
(iii) the ubiquitin ligase binding compound is selected from the group consisting of:
17. The compound of claim 16 , wherein the ubiquitin ligase binding compound is selected from the group consisting of:
18. The compound of claim 15 , wherein the compound comprises from 1 to 5 ubiquitin ligase binding compounds.
19. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the compound of claim 15 .
20. A method of treating lymphoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the compound of claim 15 .